Tutton M K, Cherry P M, Raj P S, Fsadni M G
Corneal Laser Centre, Clatterbridge Hospital, Wirral, United Kingdom.
J Cataract Refract Surg. 1996 Jun;22(5):536-41. doi: 10.1016/s0886-3350(96)80005-8.
To evaluate the efficacy and safety of diclofenac sodium 0.1% ophthalmic solution in patients having myopic photorefractive keratectomy (PRK).
Corneal Laser Centre, Clatterbridge Hospital, Wirral, United Kingdom.
We performed a prospective, randomized, double-masked, parallel-group, placebo-controlled study of 50 patients (diclofenac 25, placebo 25) of both sexes who had myopic excimer laser PRK. Results were evaluated by several types of questionnaires and comprehensive clinical examination on the day of the procedure and 1 and 3 to 14 days postoperatively.
Diclofenac-treated patients experienced significantly less photophobia, burning/stinging, and ocular pain and took significantly fewer oral narcotic analgesics over the first 24 hours postoperatively than placebo-treated patients.
Topical diclofenac significantly reduced the ocular pain and discomfort immediately after excimer PRK without any clinically significant complications or adverse effects.
评估0.1%双氯芬酸钠眼药水对接受近视性准分子激光原位角膜磨镶术(PRK)患者的疗效和安全性。
英国威尔拉尔克莱特布里奇医院角膜激光中心。
我们对50例接受近视性准分子激光PRK的患者(双氯芬酸组25例,安慰剂组25例)进行了一项前瞻性、随机、双盲、平行组、安慰剂对照研究。在手术当天以及术后1天和3至14天,通过多种问卷类型和全面的临床检查对结果进行评估。
与安慰剂治疗的患者相比,双氯芬酸治疗的患者在术后头24小时内畏光、烧灼感/刺痛感和眼痛明显减轻,口服麻醉性镇痛药的使用量也明显减少。
局部使用双氯芬酸可在准分子激光PRK术后立即显著减轻眼痛和不适,且无任何具有临床意义的并发症或不良反应。